NYSE:EBS - Emergent Biosolutions Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$44.24 -1.00 (-2.21 %)
(As of 05/19/2019 04:00 PM ET)
Previous Close$44.24
Today's Range$44.24 - $45.89
52-Week Range$43.35 - $73.89
Volume471,101 shs
Average Volume521,671 shs
Market Capitalization$2.27 billion
P/E Ratio18.99
Dividend YieldN/A
Beta1.31
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids. The company offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. It also provides NARCAN for the emergency treatment of known or suspected opioid overdose; RSDL (Reactive Skin Decontamination Lotion Kit), a medical device to remove or neutralize chemical warfare agents from the skin; and Trobigard for intramuscular self-injection of atropine sulfate and obidoxime chloride. In addition, the company offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; BAT (Botulism Antitoxin Heptavalent) for treating botulinum disease; and VIGIV (vaccinia immune globulin intravenous) that addresses complications from smallpox vaccination. Further, it provides NuThrax, an anthrax vaccine; CHIKUNGUNYA, a chikungunya virus-like particle vaccine; ADENOVIRUS 4/7, a live attenuated vaccine; rVSV-Lassa, a vaccine for prevention of Lassa fever; rVSV-Marburg, a vaccine for prevention of Marburg hemorrhagic fever; rVSV-Sudan, vaccine for prevention of Sudan hemorrhagic fever; rVSV-QUAD, a vaccine for prevention of hemorrhagic fever; and rVSV-Ebola, a vaccine for prevention of Ebola hemorrhagic fever. Additionally, the company offers FLU-IGIV to treat Influenza A infection in hospitalized patients; and ZIKV-IG, a prophylaxis for Zika infections, as well as contract manufacturing services to third-party customers. Emergent BioSolutions Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.

Receive EBS News and Ratings via Email

Sign-up to receive the latest news and ratings for EBS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
CUSIP29089Q10
Phone240-631-3200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$782.40 million
Cash Flow$3.5677 per share
Book Value$19.21 per share

Profitability

Net Income$62.70 million

Miscellaneous

Employees1,705
Market Cap$2.27 billion
Next Earnings Date8/1/2019 (Estimated)
OptionableOptionable

Emergent Biosolutions (NYSE:EBS) Frequently Asked Questions

What is Emergent Biosolutions' stock symbol?

Emergent Biosolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS."

How will Emergent Biosolutions' stock buyback program work?

Emergent Biosolutions declared that its Board of Directors has initiated a share repurchase program on Friday, March 23rd 2018, which permits the company to repurchase $50,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to reacquire shares of its stock through open market purchases. Shares repurchase programs are often an indication that the company's leadership believes its shares are undervalued.

How were Emergent Biosolutions' earnings last quarter?

Emergent Biosolutions Inc (NYSE:EBS) issued its earnings results on Thursday, May, 2nd. The biopharmaceutical company reported ($0.13) EPS for the quarter, missing the Zacks' consensus estimate of $0.13 by $0.26. The biopharmaceutical company had revenue of $190.60 million for the quarter, compared to the consensus estimate of $201.36 million. Emergent Biosolutions had a return on equity of 11.73% and a net margin of 4.88%. The business's revenue for the quarter was up 61.8% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.03) EPS. View Emergent Biosolutions' Earnings History.

When is Emergent Biosolutions' next earnings date?

Emergent Biosolutions is scheduled to release their next quarterly earnings announcement on Thursday, August 1st 2019. View Earnings Estimates for Emergent Biosolutions.

What guidance has Emergent Biosolutions issued on next quarter's earnings?

Emergent Biosolutions issued an update on its first quarter 2019 earnings guidance on Thursday, February, 21st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $185-205 million, compared to the consensus revenue estimate of $213.07 million.Emergent Biosolutions also updated its FY 2019 guidance to EPS.

What price target have analysts set for EBS?

6 equities research analysts have issued twelve-month target prices for Emergent Biosolutions' shares. Their predictions range from $60.00 to $80.00. On average, they anticipate Emergent Biosolutions' stock price to reach $70.3333 in the next year. This suggests a possible upside of 59.0% from the stock's current price. View Analyst Price Targets for Emergent Biosolutions.

What is the consensus analysts' recommendation for Emergent Biosolutions?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Emergent Biosolutions in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Emergent Biosolutions.

What are Wall Street analysts saying about Emergent Biosolutions stock?

Here are some recent quotes from research analysts about Emergent Biosolutions stock:
  • 1. Cantor Fitzgerald analysts commented, ". Post 1Q19, we reiterate our Overweight rating and our 12- month price target of $75. EBS continues to be the leader in the biodefense field, and the acquisition of Adapt and PaxVax leverage the company’s historical expertise, while further diversifying revenue away from BioThrax. We continue to believe the company’s business is a lot more durable than the Street is giving it credit for, and we expect Emergent to extend a number of its current contracts beyond current estimates, as well as bring some significant pipeline product to market over time. Emergent does not have the risk of commercial insurance reimbursement or payer pricing pressures on the majority of its portfolio." (5/2/2019)
  • 2. According to Zacks Investment Research, "Emergent BioSolutions' recent acquisitions of PaxVax and Adapt Pharma have expanded the company’s presence in the public health threats market. Its anthrax vaccine, NuThrax’s regulatory application is under review, with a decision expected in the first half of 2019. We are positive on Emergent’s spin-off of its biosciences business into a separate publicly traded company as it resulted in reduction of the cost structure. Notably, the company derives majority of its revenues from BioThrax sales. Hence, its sole dependence on BioThrax for revenues is a headwind. Moreover, Emergent depends on certain single-source suppliers for key materials and services, which are necessary for manufacturing BioThrax. This, in turn, raises a concern. Shares of the company have underperformed the industry so far this year. Estimates have narrowed ahead of Q1 earnings. Emergent has a mixed record of earnings surprises in the recent quarters." (4/8/2019)

Has Emergent Biosolutions been receiving favorable news coverage?

News stories about EBS stock have trended somewhat positive this week, InfoTrie Sentiment reports. The research group ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Emergent Biosolutions earned a daily sentiment score of 1.9 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Who are some of Emergent Biosolutions' key competitors?

What other stocks do shareholders of Emergent Biosolutions own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Emergent Biosolutions investors own include Mercadolibre (MELI), Global Payments (GPN), Broadcom (AVGO), NXP Semiconductors (NXPI), Netflix (NFLX), Gentherm (THRM), CalAmp (CAMP), NVIDIA (NVDA), Micron Technology (MU) and Intel (INTC).

Who are Emergent Biosolutions' key executives?

Emergent Biosolutions' management team includes the folowing people:
  • Mr. Fuad El-Hibri, Founder & Exec. Chairman (Age 61)
  • Mr. Robert G. Kramer Sr., CEO, Pres & Director (Age 62)
  • Mr. Atul Saran, Exec. VP of Corp. Devel., Gen. Counsel & Corp. Sec. (Age 46)
  • Mr. Adam R. Havey, Exec. VP of Bus. Operations (Age 48)
  • Mr. Richard S. Lindahl, Exec. VP, CFO & Treasurer (Age 55)

Who are Emergent Biosolutions' major shareholders?

Emergent Biosolutions' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (13.11%), Renaissance Technologies LLC (3.85%), Neuberger Berman Group LLC (3.74%), Dimensional Fund Advisors LP (3.10%), Rice Hall James & Associates LLC (2.38%) and Northern Trust Corp (1.76%). Company insiders that own Emergent Biosolutions stock include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri, George A Joulwan, Jerome M Hauer, Kathryn C Zoon, Ronald Richard, Sue Bailey and Zsolt Harsanyi. View Institutional Ownership Trends for Emergent Biosolutions.

Which major investors are selling Emergent Biosolutions stock?

EBS stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Acadian Asset Management LLC, Rice Hall James & Associates LLC, Man Group plc, Morgan Stanley, Dimensional Fund Advisors LP, New Amsterdam Partners LLC NY and Phocas Financial Corp.. Company insiders that have sold Emergent Biosolutions company stock in the last year include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri, George A Joulwan, Kathryn C Zoon, Ronald Richard and Sue Bailey. View Insider Buying and Selling for Emergent Biosolutions.

Which major investors are buying Emergent Biosolutions stock?

EBS stock was purchased by a variety of institutional investors in the last quarter, including Neuberger Berman Group LLC, Vaughan Nelson Investment Management L.P., The Manufacturers Life Insurance Company , Renaissance Technologies LLC, Jennison Associates LLC, BlackRock Inc., Sio Capital Management LLC and Pier Capital LLC. View Insider Buying and Selling for Emergent Biosolutions.

How do I buy shares of Emergent Biosolutions?

Shares of EBS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Emergent Biosolutions' stock price today?

One share of EBS stock can currently be purchased for approximately $44.24.

How big of a company is Emergent Biosolutions?

Emergent Biosolutions has a market capitalization of $2.27 billion and generates $782.40 million in revenue each year. The biopharmaceutical company earns $62.70 million in net income (profit) each year or $2.33 on an earnings per share basis. Emergent Biosolutions employs 1,705 workers across the globe.

What is Emergent Biosolutions' official website?

The official website for Emergent Biosolutions is http://www.emergentbiosolutions.com.

How can I contact Emergent Biosolutions?

Emergent Biosolutions' mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The biopharmaceutical company can be reached via phone at 240-631-3200 or via email at [email protected]


MarketBeat Community Rating for Emergent Biosolutions (NYSE EBS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  325 (Vote Outperform)
Underperform Votes:  279 (Vote Underperform)
Total Votes:  604
MarketBeat's community ratings are surveys of what our community members think about Emergent Biosolutions and other stocks. Vote "Outperform" if you believe EBS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EBS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/19/2019 by MarketBeat.com Staff

Featured Article: What Are Treasury Bonds?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel